Hybridon, Inc

Hybridon, Inc (Amex: HBY) was a biotechnology company based in Cambridge, MA, specializing in the discovery and development of novel therapeutics and diagnostics using synthetic DNA, that merged with Idera Pharmaceuticals in 2004.

Notable investors

Hybridon was as notable for is interesting roster of investors as well as for its technologies and products. According to an SEC filing of May 4, 1999 [ [http://www.secinfo.com/ds4Px.6yz.htm DEFR14A for Hybridon, Inc, filed 5/4/99] ] Hybridon had a number of interesting investors with 5% or more ownership including:
* Abdullah bin Mahfouz, son of the more widely-known Khalid bin Mahfouz (13/87%), along with the Bermuda-based Mahfouz proprietary Intercity Holdings (13.87%);
* Yahia M. A. Laden (8.67%), half-brother of the more famous Osama bin Laden;
* Nicris Limited, directed by Yehia bin Laden, and represented by Magnin Dunand et Associées (8.59%)
* Faisal Finance Switzerland, the first Islamic bank registered in Switzerland, and a fully-owned subsidiary of Dar al-Maal al-Islami Trust, recently under investigation by the U.S. Department of Justice in two separate terrorism financing probes. [cite web
title = Terror Inquiry Turns to Tax Law: Efforts to Probe Financing Of Islamic Extremists Centers on IRS Violations
author = GLENN R. SIMPSON
date = January 31, 2007
page = A3
publisher = Wall Street Journal
url = http://online.wsj.com/article_email/SB117021371480893282-lMyQjAxMDE3NzMwMTIzMTEzWj.html ] (6.58%).

External links

* [http://www.lifesciencesworld.com/directory/view/548/H?page=4 Life Sciences World profile]

References